EP 0863752 B1 20030219 - USE OF ALLYLAMINE DERIVATIVES SUCH AS TERBINAFINE, IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTION OF ASSOCIATED DISEASES

Title (en)

USE OF ALLYLAMINE DERIVATIVES SUCH AS TERBINAFINE, IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTION OF ASSOCIATED DISEASES

Title (de)

VERWENDUNG VON ALLYLAMINDERIVATEN WIE TERBINAFIN ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR BEHANDLUNG VON MIT EINER HELICOBACTER PYLORI INFEKTION ZUSAMMENHÄNGENDEN ERKRANKUNGEN

Title (fr)

UTILISATION DES DERIVES DE ALLYLAMINE TELS QUE LA TERBINAFINE DANS LA FABRICATION D'UN MEDICAMENT POUR LE TRAITEMENT D'UNE INFECTION PAR HELICOBACTER PYLORI DE MALADIES ASSOCIEES

Publication

EP 0863752 B1 20030219 (EN)

Application

EP 96924889 A 19960705

Priority

EP 9602970 W 19960705
GB 9513750 A 19950706

Abstract (en)

[origin: WO9702026A1] Use of compounds of formula (I), wherein R has various significances, in free base form or in pharmaceutically acceptable salt form, as agents against H. pylori infection and associated diseases.

IPC 1-7

A61K 31/135; A61P 1/04; A61P 31/10; A61P 35/00

IPC 8 full level

A61K 31/135 (2006.01); A61K 31/137 (2006.01); A61K 31/445 (2006.01); A61K 31/4458 (2006.01); C07D 211/14 (2006.01); A61K 31/70 (2006.01); A61P 1/00 (2006.01); A61P 1/04 (2006.01); A61P 31/04 (2006.01); A61P 31/10 (2006.01); A61P 35/00 (2006.01)

CPC (source: EP KR US)

A61K 31/13 (2013.01 - KR); A61K 31/137 (2013.01 - EP US); A61K 31/445 (2013.01 - EP US); A61K 31/4458 (2013.01 - EP US); A61K 31/70 (2013.01 - EP US); A61P 1/00 (2018.01 - EP); A61P 1/04 (2018.01 - EP); A61P 1/14 (2018.01 - EP); A61P 31/04 (2018.01 - EP); A61P 31/10 (2018.01 - EP); A61P 35/00 (2018.01 - EP)

C-Set (source: EP US)

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)

WO 9702026 A1 19970123; AT E232723 T1 20030315; AU 6519596 A 19970205; AU 715270 B2 20000120; CA 2219678 A1 19970123; CA 2219678 C 20061010; CN 1189775 A 19980805; CN 1204881 C 20050608; CY 2465 B1 20050603; CZ 1798 A3 19980318; CZ 289440 B6 20020116; DE 69626301 D1 20030327; DE 69626301 T2 20031016; DK 0863752 T3 20030422; EP 0863752 A1 19980916; EP 0863752 B1 20030219; ES 2192608 T3 20031016; GB 9513750 D0 19950906; HK 1011527 A1 19990716; HU 224311 B1 20050728; HU P9802929 A2 19990928; HU P9802929 A3 19991028; IL 122853 A0 19980816; IL 122853 A 20010430; JP 3680950 B2 20050810; JP H11508580 A 19990727; KR 100425401 B1 20040716; KR 19990028725 A 19990415; MX 9710093 A 19980331; MY 132436 A 20071031; NO 317496 B1 20041108; NO 975790 D0 19971209; NO 975790 L 19971209; PL 187704 B1 20040930; PL 323305 A1 19980316; RU 2193402 C2 20021127; SI 0863752 T1 20030630; SK 282874 B6 20030109; SK 698 A3 19980506; TW 522011 B 20030301; US 5935998 A 19990810; ZA 965749 B 19980105

DOCDB simple family (application)

EP 9602970 W 19960705; AT 96924889 T 19960705; AU 6519596 A 19960705; CA 2219678 A 19960705; CN 96195289 A 19960705; CY 0400055 A 20040702; CZ 1798 A 19960705; DE 69626301 T 19960705; DK 96924889 T 19960705; EP 96924889 A 19960705; ES 96924889 T 19960705; GB 9513750 A 19950706; HK 98112906 A 19981207; HU P9802929 A 19960705; IL 12285396 A 19960705; JP 50483397 A 19960705; KR 19980700023 A 19980105; MX 9710093 A 19960705; MY PI19962783 A 19960705; NO 975790 A 19971209; PL 32330596 A 19960705; RU 98102187 A 19960705; SI 9630594 T 19960705; SK 698 A 19960705; TW 85108161 A 19960706; US 98132498 A 19980106; ZA 965749 A 19960705